<DOC>
	<DOCNO>NCT02887677</DOCNO>
	<brief_summary>This study design test hypothesis treatment-induced reduction ambulatory aortic pressure pronounce group dapagliflozin group placebo . It 12 week , double-blind , randomize , placebo-controlled clinical trial dapagliflozin versus placebo 160 adult patient type 2 diabetes mellitus ( DM ) . It conduct three center . Potentially eligible patient ask provide write informed consent ( Screening Visit ) . Patients , fulfill inclusion exclusion criterion , ask visit site one week ( Visit 1 - V1 ) screen visit . On Visit 2 ( V2 ) eligible patient randomize one two treatment arm continue next visit appropriate ( Visit 3 , Telephone Visit 1 , Visit 4-end study ) . Aortic blood pressure ( BP ) arterial stiffness parameter measure indicated protocol V1 V3 Mobil-O-Graph monitor . Blood sample collect indicated protocol Screening Visit measurement glycated hemoglobin ( HbA1c ) , creatinine liver function parameter . In addition , blood sample collect V1 V3 routine hematological biochemical test include creatinine , fast glucose , HbA1c , lipid profile liver function parameter . Urine sample collect indicated protocol V1 V3 measurement albumin creatinine ratio .</brief_summary>
	<brief_title>Effects Dapagliflozin Central Hemodynamics Urine Albumin Excretion Patients With Type 2 Diabetes .</brief_title>
	<detailed_description>Study design Screening visit : Potentially eligible patient ask provide write informed consent . The investigator record full medical history , clinical examination , demographic characteristic , electrocardiogram ( ECG ) , body weight , height , body mass index ( BMI ) waist perimeter . Office blood pressure ( BP ) measure physician three time use mercury sphygmomanometer [ cuff place level brachial artery three minute interval intercept measurement , follow 10 minute rest seat position ( cuff cover least 80 % brachial circumference 2/3 brachial length. ) ] . The investigator also collect blood sample determine glycated hemoglobin ( HbA1C ) , creatinine , glomerular filtration rate ( GFR ) liver function . Visit 1 ( V1 ) : Patients , fulfill inclusion exclusion criterion , ask visit site 1 week screen visit ( +/-2 day ) , follow 12-hour fast . Three measurement office BP level brachial artery , three minute interval measurement , perform use mercury sphygmomanometer , 10 minutes-rest sit posture ( cuff bladder size encircle least 80 % arm circumference cover two third arm length ) . After , venous blood specimen spot urine specimen collect relevant blood test albumin/creatinine ratio ( ACR ) respectively . Subsequently , Mobil-O-Graph monitor cuff appropriate size fit BP record initiate 24 hour . The device program collect data every 20 minute , except 23:00 07:00 ( data collection every 30 minute ) . Visit 2 ( V2 ) : An appointment schedule following day patient drop-off Mobil-O-Graph device . Patients randomize 1:1 ratio dapagliflozin placebo group start receive drug regimen day . Moreover , patient receive dietary lifestyle advice commence visit . Telephone Visit 1 ( ΤV1 ) : A telephone visit ( TV1 ) schedule 6 week V2 ( +/-2 day ) . Patient history obtain , emphasize possible adverse event previous 6 week . Home blood glucose level , available , would also discuss . Visit 3 ( V3 ) : Visit 3 schedule 6 week telephone visit 1 ( TV1 ) ( +/-2 day ) . The following parameter determine : medical history last week , clinical examination ( include three brachial BP measurement mercury sphygmomanometer mention ) , venous blood specimen collection ( 12-hour fast ) initiation 24-hour ambulatory blood pressure monitoring ( ABPM ) ( Mobil-O-Graph device ) . The patient also provide spot urine specimen ACR evaluation . Visit 4 ( V4 ) : Visit 4 schedule 1 day visit 3 . Patients drop-off Mobil-O-Graph device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Age &gt; 18 &lt; 70 year old Type 2 diabetes mellitus Glycated hemoglobin &gt; 7 % &lt; 9 % Patients stable dose metformin least 1500 mg past 3 month . Patient provide inform consent Hypovolemic patient . Patients loop diuretic . Patients low BP ( office SBP &lt; 110 mmHg ) orthostatic hypotension ( BP drop &gt; 20 mmHg SBP &lt; 110 mmHg stand position 1 min ) . Patients antidiabetic drug metformin . Secondary hypertension . Stage 2 hypertension high ( office SBP ≥160 mmHg DBP ≥100 mmHg ) . Chronic kidney disease stage 3 high ( GFR &lt; 60 mL/min/1.73 m2 ) . Myocardial infarction unstable angina episode within past 3 month , congestive heart failure class IIIIV accord New York Heart Association criterion . Pregnancy childbearing potential [ define woman enter menses postmenopausal ( menopause define absence menses least 12 month without medical cause woman typical age ) woman subject permanent sterilization ( ie . tubal ligation , hysterectomy , bilateral oophorectomy bilateral salpingectomy ) ] . History liver disease significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN total bilirubin &gt; 2.0 mg/dL . History malignancy organ system ( resect basal cell carcinoma consider cured exempt ) within past 5 year prior Visit 1 ( V1 ) . History drug alcohol abuse within last one year . Any contraindication history hypersensitivity study drug drug similar chemical structure . Any surgical medical condition , opinion investigator , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period . Intake investigational drug another trial within 30 day prior Visit 1 ( V1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>Arterial Stiffness</keyword>
	<keyword>Aortic Pressure</keyword>
</DOC>